UNSPSC 51432806: Enalapril maleate

This classification denotes an ace inhibitor with the molecular formula C20H28N2O5.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9O25354EPJ, chemically known as l-proline, n-((1s)-1-(ethoxycarbonyl)-3-phenylpropyl)-l-alanyl- but more generally known as enalapril maleate, which bears US NIH Compound Identifier 5362032. European Medicines Agency schedules Enalapril maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01884MIG.

Most nations, for tariff and trade purposes, schedule enalapril maleate under HS 29339990 and SITC 51577. As of Q4 2014, ENALAPRIL MALEATE remains US FDA's Preferred Term for this commodity. Enalapril maleate bears US NLM identifiers UMLS ID C0600128 and NCI Concept Code C468. SMILES: CCOC(=O)[C@H](CCC1CCCCC1)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)O.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51432806 Enalapril maleate is a Commodity code covering specific pharmaceutical active ingredients and formulations used by emergency medical services, public health agencies, and healthcare systems across state and local government. State and local governments procure this medication—and closely related advanced life support drugs—through sealed-bid and cooperative purchasing vehicles for fire rescue services, EMS systems, and multistate health benefit programs. The work involves direct supply of pharmaceutical products meeting FDA and cGMP compliance, with vendors typically managing inventory rotation, expiration-date tracking, and delivery schedules aligned to nine-month or longer shelf-life requirements. Issuing bodies include municipal purchasing departments (fire and EMS), state health and human services agencies, and multistate cooperative purchasing consortia such as MMCAP. These jurisdictions are often repeat buyers managing ongoing medication inventory for emergency response and state employee health benefit programs.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued a sealed-bid solicitation (26P00188, due April 8, 2026) for Advanced Life Support Medications, including epinephrine, adenosine, diltiazem, and labetalol, for Tampa Fire Rescue with an estimated contract value of $40,000 and a one-year term plus renewal options; the solicitation carried a 5 percent SLBE bid discount and required vendors to maintain nine-month-plus expiration dates and arrange expired-material replacement. The Texas Health and Human Services Commission posted an RFI (HHS0017013, April 3, 2026 response deadline) exploring direct-to-manufacturer prescription fulfillment models outside traditional PBM and GPO channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, requiring vendors to meet cGMP and DSCSA certification, maintain wholesaler relationships, and comply with a 3 percent administrative fee structure.